Last reviewed · How we verify

AZT — Competitive Intelligence Brief

AZT (AZT) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside reverse transcriptase inhibitor (NRTI). Area: Infectious Disease / Virology.

marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase Infectious Disease / Virology Small molecule Live · refreshed every 30 min

Target snapshot

AZT (AZT) — Johns Hopkins Bloomberg School of Public Health. AZT (zidovudine) inhibits HIV reverse transcriptase, preventing the virus from converting its RNA genome into DNA and replicating within host cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AZT TARGET AZT Johns Hopkins Bloomberg School of Public Health marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
Doravirine, Tenofovir, Lamivudine Doravirine, Tenofovir, Lamivudine Merck Sharp & Dohme LLC marketed Antiretroviral combination (NNRTI + NRTIs) HIV reverse transcriptase, HIV integrase
Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir St Stephens Aids Trust marketed Antiretroviral agents (INSTI, NNRTI, NRTI/NtRTI) HIV integrase (dolutegravir); HIV reverse transcriptase (efavirenz and combination); HIV entry (tenofovir/emtricitabine component)
Eviplera® Eviplera® St Stephens Aids Trust marketed Antiretroviral combination therapy (NNRTI + NRTI + NtRTI) HIV reverse transcriptase, HIV integrase
FTC/TAF FTC/TAF ViiV Healthcare marketed Nucleoside/nucleotide reverse transcriptase inhibitor combination HIV reverse transcriptase
ZIAGEN® ZIAGEN® ViiV Healthcare marketed Nucleoside reverse transcriptase inhibitor (NRTI) HIV reverse transcriptase
zidovudine+lamivudine+lopinavir/ritonavir zidovudine+lamivudine+lopinavir/ritonavir Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran marketed Antiretroviral combination therapy (NRTI + PI) HIV reverse transcriptase and HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside reverse transcriptase inhibitor (NRTI) class)

  1. French National Agency for Research on AIDS and Viral Hepatitis · 3 drugs in this class
  2. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
  3. ViiV Healthcare · 2 drugs in this class
  4. Nanfang Hospital, Southern Medical University · 2 drugs in this class
  5. Asan Medical Center · 1 drug in this class
  6. Dong-A ST Co., Ltd. · 1 drug in this class
  7. Bristol-Myers Squibb · 1 drug in this class
  8. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
  9. Fu-Sheng Wang · 1 drug in this class
  10. Avexa · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AZT — Competitive Intelligence Brief. https://druglandscape.com/ci/azt. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: